医学
重症监护室
回顾性队列研究
2019年冠状病毒病(COVID-19)
怀孕
新生儿重症监护室
疾病
队列研究
冠状病毒
疾病严重程度
重症监护
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
队列
儿科
急诊医学
重症监护医学
内科学
传染病(医学专业)
生物
遗传学
作者
Joe Eid,Mahmoud Abdelwahab,Nora Colburn,Shandra R. Day,Michael Cackovic,Kara M. Rood,Maged M. Costantine
标识
DOI:10.1097/aog.0000000000004734
摘要
Remdesivir has been shown to shorten the time to recovery in hospitalized patients with coronavirus disease 2019 (COVID-19). Data on its use in pregnancy are limited. In this single-center retrospective cohort study, our objective was to determine whether early remdesivir use in pregnant individuals is associated with decreased risk of admission to the intensive care unit (ICU). Forty-one pregnant patients were included in this study, and outcomes were compared between those who received remdesivir less than 7 days (early group) and 7 or more days (late group) from onset of patient-reported symptoms. Early remdesivir administration was associated with improved clinical outcomes, including lower rates of ICU admission, decreased length of hospitalization, and decreased progression to critical disease in pregnant individuals hospitalized with COVID-19.
科研通智能强力驱动
Strongly Powered by AbleSci AI